Immutep Ltd., a late-stage immunotherapy company, has announced the successful attainment of a grant from the Polish government for its EFTISARC-NEO Phase II trial. This trial evaluates the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® (pembrolizumab) in the treatment of resectable soft tissue sarcoma $(STS.UK)$. The funding, awarded by the Polish Medical Research Agency program, supports this innovative study, which has shown promising results by exceeding its primary endpoint of tumour hyalinization/fibrosis. This development highlights the potential of the novel combination therapy in addressing the high unmet medical need in STS, an aggressive orphan cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。